Puma Biotechnology
Puma Biotechnology is a biopharmaceutical company dedicated to the acquisition, development, and commercialization of novel therapeutics for the treatment of cancer.
Home About Us Product Pipeline News Investors Contacts Careers

News

Recent Press Releases Archives

Recent Press Releases

2022 News Releases

Dec. 7, 2022 - Puma Biotechnology Presents Updated Findings from the TBCRC-022 Trial at the 2022 San Antonio Breast Cancer Symposium
Read

Dec. 5, 2022 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Read

Nov. 3, 2022 - Puma Biotechnology Reports Third Quarter 2022 Financial Results
- Raises FY 2022 NERLYNX Net Product Revenue Guidance
Read

Nov. 2, 2022 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Read

Oct. 27, 2022 - Puma Biotechnology Presents Updated Findings from the Phase II SUMMIT Basket Trial of Neratinib in EGFR Exon 18-Mutant NSCLC at the 2022 EORTC/NCI/AACR Symposium
Read

Oct. 20, 2022 - Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results
Read

Oct. 4, 2022 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Read

Sept. 20, 2022 - Puma Biotechnology Announces Exclusive License Agreement with Takeda for the Development and Commercialization of Alisertib, an Investigational Aurora Kinase A Inhibitor
Read

Sept. 11, 2022 - Puma Biotechnology Presents Updated Findings from the Phase II SUMMIT Basket Trial of Neratinib for HER2-Mutant, Recurrent/Metastatic Cervical Cancer at the ESMO Congress 2022
Read

Sept. 6, 2022 - Puma Biotechnology to Present at the H.C. Wainwright 24th Annual Global Investment Conference
Read

Sept. 2, 2022 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Read

Aug. 5, 2022 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Read

Aug. 4, 2022 - Puma Biotechnology Reports Second Quarter 2022 Financial Results
Read

July 21, 2022 - Puma Biotechnology to Host Conference Call to Discuss Second Quarter Financial Results
Read

July 6, 2022 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Read

June 7, 2022 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Read

June 6, 2022 - Puma Biotechnology Presents Outcomes from the Metastatic Breast Cancer Cohort of the SUMMIT Trial at the ASCO 2022 Annual Meeting
Read

June 4, 2022 - Puma Biotechnology Presents Final Results from the Biliary Tract Cohort of the Phase 2 SUMMIT ‘Basket’ Trial of Neratinib at the ASCO 2022 Annual Meeting
Read

May 26, 2022 - Puma Biotechnology Announces Publication of Abstracts on Neratinib for the 2022 ASCO Annual Meeting
Read

May 11, 2022 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Read

May 5, 2022 - Puma Biotechnology Reports First Quarter 2022 Financial Results
Read

April 27, 2022 - Puma Biotechnology Announces Publication of Neratinib Abstract Titles for the 2022 ASCO Annual Meeting
Read

April 21, 2022 - Puma Biotechnology to Host Conference Call to Discuss First Quarter Financial Results
Read

April 5, 2022 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Read

March 10, 2022 - Puma Biotechnology Announces $10 Million Private Placement
Read

March 7, 2022 - Puma Biotechnology to Participate in Breast Cancer Panel at Cowen’s Annual Health Care Conference
Read

March 4, 2022 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Read

March 3, 2022 - Puma Biotechnology Reports Fourth Quarter and Full Year Financial Results
Read

February 16, 2022 - Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2021 Financial Results
Read

February 3, 2022 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Read

January 20, 2022 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Read

January 12, 2022 - Puma Biotechnology’s NERLYNX® Included in Two Important NCCN Clinical Practice Guideline Updates for the Treatment of Breast Cancer
Read

January 10, 2022 - Puma Biotechnology Releases Updated Corporate Presentation
Read

January 4, 2022 - Puma Biotechnology to Present at the H.C. Wainwright BioConnect Conference
Read




Corporate Fact Sheet

Puma Biotechnology, Inc.

10880 Wilshire Blvd., Suite 2150
Los Angeles, CA 90024
424-248-6500 Main
424-248-6501 Fax